In addition, among localized prostate cancers under active surveillance in the United States, prostate cancer patients with germline BRCA1/BRCA2 or ATM pathogenic variants were 1.96 times more likely to be upgraded on re-biopsy specimens than prostate cancer patients without pathogenic variants [24]. This evidence concerns the gene BRCA2 and Familial prostate cancer.